Physician profile
Jaydev Kesrani
NPI 1275915563
$2,508.39
in general payments reported to CMS, 2019-2025
23 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $785 · 2024: $1,180 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.72 |
| Education | $822.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $848.97 | 2022-2025 | Erleada, Akeega, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $266.15 | 2023-2025 | Enhertu, Lynparza |
| Amgen INC. | $213.64 | 2023-2024 | Lumakras |
| Sanofi-Aventis U.S. LLC | $174.98 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $159.77 | 2023 | Monoferric |
| Genzyme Corporation | $121.76 | 2023-2025 | |
| Seagen INC. | $114.27 | 2022 | |
| Daiichi Sankyo INC. | $98.99 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $94.53 | 2023-2025 | Zejula, Jemperli, Shingrix |
| Janssen Scientific Affairs, LLC | $67.98 | 2023-2024 | Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $52.99 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
| Puma Biotechnology, INC. | $47.72 | 2023-2025 | |
| Pfizer INC. | $38.88 | 2023 | |
| Celgene Corporation | $28.63 | 2023-2025 | Reblozyl, Pomalyst |
| Mirati Therapeutics, INC. | $25.00 | 2023 | Krazati |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $22.10 | 2022 | |
| Genentech USA, INC. | $21.67 | 2024 | Phesgo |
| Alexion Pharmaceuticals, INC. | $21.52 | 2024 | Ultomiris |
| Genmab U.S., INC. | $20.36 | 2023 | Tivdak |
| Incyte Corporation | $18.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.85 | 2024 | |
| Taiho Oncology, INC. | $15.93 | 2024 | |
| Eisai INC. | $15.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaydev Kesrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.